It starts with a sniffle. A mild cough. You tell yourself it’s just a cold—babies get those, right? But make no mistake. RSV ...

Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory infections (ALRTIs) in children under five and poses a persistent ...

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...

In a major boost for infant health, the U.S. Food and Drug Administration (FDA) has approved ENFLONSIA ™ (clesrovimab-cfor), ...

Respiratory Syncytial Virus (RSV) poses a significant threat to Indian infants, particularly during post-monsoon and winter, contributing substantiall ...

The flu virus is lingering in Arizona and the season has been vicious. Pediatric flu deaths reached the highest level in ...

The U.S. Food and Drug Administration expanded approval of Moderna Inc.'s (NASDAQ: MRNA) respiratory syncytial virus vaccine.

MPV tends to hit hardest in young children, older adults and people with weakened immune systems. A virologist explains.